 |
200 Diseases |  |
192 Trials |
|
192 Trials |  |
21170 News |  |
| «12...167168169170171172173174175176177...224225» |
- |||| Humira (adalimumab) / Eisai, AbbVie, Cosentyx (secukinumab) / Novartis
Secukinumab is not stat superior to Adalimumab for primary endpoint in PsA. Equal but some features are better. Do 2 IL17 H2H trials make you change order of biological Rx? #RWCS2020 @RheumNow (Twitter) - Feb 14, 2020
- |||| Humira (adalimumab) / Eisai, AbbVie
Head-to-Head: Head to head Ixe vs Adalimumab in PsA is superior on skin with Ixe and equal on jts. MTX was allowed and seemed to improve Adalimumab response not true for Ixe. May change Rx landscape in PsA. #RWCS2020 @RheumNow (Twitter) - Feb 14, 2020
- ||| Humira (adalimumab) / Eisai, AbbVie
Axial SpA if on adalimumab should MTX be used to decrease ABs? Study says YE and pretreat so MTX first. Not standard of care. #RWCS2020 @RheumNow (Twitter) - Feb 14, 2020
- | Humira (adalimumab) / Eisai, AbbVie
Journal: The effectiveness of adalimumab treatment for non-infectious uveitis. (Pubmed Central) - Feb 14, 2020
An anti-TNF-α agent, adalimumab, was recently approved for the treatment of refractory non-infectious uveitis. In this review, we provide an introduction to uveitis and summarize the effectiveness and safety of adalimumab in the treatment of non-infectious uveitis.
- ||| Humira (adalimumab) / Eisai, AbbVie
Many brands of adalimumab available in Europe (Twitter) - Feb 14, 2020
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week). (Pubmed Central) - Feb 14, 2020
Here we present a 45-year-old male patient who suffered from psoriatic arthritis (PsA), for which adalimumab (80 mg every other week) was effective. Dose escalation of a TNF-α antagonist should be considered for patients showing an inadequate response for disease stabilization in PsA.
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: If your aim is to prevent immunogenicity that is true. Underpowered to demonstrate clinical benefit for combo treatment for adalimumab (Twitter) - Feb 14, 2020
- | Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Journal: Persistence with biological drugs in psoriasis patients followed in dermatology practices in Germany: A retrospective cohort study of 1,201 patients. (Pubmed Central) - Feb 14, 2020
Dose escalation of a TNF-α antagonist should be considered for patients showing an inadequate response for disease stabilization in PsA. Persistence with biological drugs in psoriasis patients followed in dermatology practices was low 3 years after therapy initiation and varied between practices.
- || Humira (adalimumab) / Eisai, AbbVie, Otezla (apremilast) / Amgen
Clinical, Journal: Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature. (Pubmed Central) - Feb 14, 2020
Persistence with biological drugs in psoriasis patients followed in dermatology practices was low 3 years after therapy initiation and varied between practices. We report the "real-life" use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Journal: Prompting Fab Yeast Surface Display Efficiency by ER Retention and Molecular Chaperon Co-expression. (Pubmed Central) - Feb 13, 2020
Moreover, fusing ER retention sequences (ERSs) with light chain also enhanced Fab display quality at the expense of display quantity, and the degree of improvements was correlated with the strength of ERSs and was more significant for Infliximab than Adalimumab. The feasibility of affinity maturation was further demonstrated by isolating a high affinity Fab clone from 1:10 or 1:10 spiked libraries.
- ||||| Humira (adalimumab) / Eisai, AbbVie
Clinical: JIA uveitis. Think of +ANA pauciarticular pts at high risk. Often chronic uveitis asymptotic so reg eye tests needed. + data with less Rx failure with adalimumab vs placebo Alvin Wells @RheumNow #RWCS2020 (Twitter) - Feb 13, 2020
- |||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Adalimumab seeems better than infliximab Behcet’s uveitis. Alvin Wells #RWCS2020 @RheumNow (Twitter) - Feb 13, 2020
- |||| Humira (adalimumab) / Eisai, AbbVie
HEOR: I fully accept your latter points. I would start my reform efforts with specialties that really drive US healthcare costs, and drug costs in particular, rather than an arm (ID) where entire branded drug market ($750M) is fraction of that for one immunomodulator (Humira, $20B) (Twitter) - Feb 13, 2020
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal, Adverse drug reaction: Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting. (Pubmed Central) - Feb 13, 2020
Our results suggested that the predominance of ADRs induced by adalimumab in females was because of their relatively lower BW. This suggests the importance of BW as a determining factor in sex disparity of ADR occurrences.
- ||| Humira (adalimumab) / Eisai, AbbVie
So there does seem to be incremental benefit of weekly adalimumab over every other week at week 52 in UC. Interesting to see that in the TDM arm the results were halfway between weekly and every other week #ECCO2020 (Twitter) - Feb 13, 2020
- ||| Humira (adalimumab) / Eisai, AbbVie
#ECCO2020 higher responders at week 8 on weekly Adalimumab vs EOW (Twitter) - Feb 13, 2020
- |||| Humira (adalimumab) / Eisai, AbbVie
#ECCO20 off to a great start! @JeanFredericCo1 presenting results from SERENE-UC Japan study of increased dosing of Adalimumab #IBD @MSHS_IBDCenter @MountSinaiNYC (Twitter) - Feb 13, 2020
- |||| Humira (adalimumab) / Eisai, AbbVie
Clinical: #UCSERENE maintenance Phase presented by #Colombel at #ECCO2020 . Difficult tot drive robust conclusions... Which dose of adalimumab should we use in #UC initial responders from now on???? (Twitter) - Feb 13, 2020
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Enrollment change: RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation (clinicaltrials.gov) - Feb 13, 2020
P4, N=208, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
This suggests the importance of BW as a determining factor in sex disparity of ADR occurrences. N=400 --> 208
- |||| Humira (adalimumab) / AbbVie
Enrollment open, Trial primary completion date: A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab (clinicaltrials.gov) - Feb 11, 2020
P4, N=238, Recruiting, Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
N=400 --> 208 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2022 --> Jan 2022
- Humira (adalimumab) / Eisai, AbbVie
A Randomized Controlled Trial to Compare the Efficacy of Intra -Articular AdalimumabVersus Intra - Articular Hyaluronic Acid in Primary Osteoarthritis of the Knee () - Feb 11, 2020 - Abstract #ISPRM2020ISPRM_371;
Conclusions : Adalimumab by a USG-guided intra-articular injection was more efficacious as compared to a USG-guided intra-articular injecton of Hyaluronic Acid for both pain and quality of life. There were no structure-modifying effects noticed at the 12 weeks follow-up.
- ||||||| Humira (adalimumab) / AbbVie
Trial completion: Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Feb 11, 2020
P3, N=514, Completed, Sponsor: AbbVie
There were no structure-modifying effects noticed at the 12 weeks follow-up. Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
@abbvie why did I wait this long to get humira without citric acid. I barely even felt the damn pen god bless (Twitter) - Feb 10, 2020
- | Humira (adalimumab) / Eisai, AbbVie
Interesting comments from @abbvie's CEO on expected decline in Humira sales, and how its experience in European markets suggest the drop might not be as steep as first predicted $ABBV (Twitter) - Feb 10, 2020
- ||| New Am Gastroenterology Assn Guidelines on Rx of Ulcerative colitis list infliximab, adalimumab, golimumab, vedolizumab, ustekinumab and tofacitinib for moderate to severe UC. Rec against TOFA until failing a TNFi; against using MTX. https://t.co/b0Xap3ijK7 (Twitter) - Feb 10, 2020
- |||||| Abrilada (adalimumab-afzb) / Pfizer
Enrollment open, Combination therapy: A Comparative Study Between PF-06410293 and Humira (clinicaltrials.gov) - Feb 9, 2020
P3, N=420, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Humira (adalimumab) / AbbVie
Enrollment open: ADAPT: Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence (clinicaltrials.gov) - Feb 9, 2020
P=N/A, N=84, Recruiting, Sponsor: University Hospital, Montpellier
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Humira (adalimumab) / Eisai, AbbVie
That's why you used the patent laws to jack up the price of Humira. Thanks. (Twitter) - Feb 9, 2020
- Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
TREMFY (guselkumab) First-line Biologic with Clinical Data vs Adalimumab and vs Secukinumab (IES) (Promenade Ballroom) - Feb 9, 2020 - Abstract #WCDC2020WCDC_64;
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Long-term outcomes of Proactive therapeutic drug monitoring of adalimumab and standard of care in patients with inflammatory bowel disease. (Pubmed Central) - Feb 9, 2020
Not yet recruiting --> Recruiting No abstract available
- [VIRTUAL] A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_927;
Alternatively, the infused donor graft may have provided a non-CD3+, non-CD33+ non-hematopoietic type of stem cell such as donor mesenchymal stem cells that in theory could facilitate a durable remission. Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053
- || Clinical, Journal: Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients. (Pubmed Central) - Feb 7, 2020
Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053 Preoperative exposure to anti-TNF biologic therapy does not add to overall or infectious 30-day postoperative morbidity in pediatric CD patients.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Review, Journal: Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. (Pubmed Central) - Feb 7, 2020
Preoperative exposure to anti-TNF biologic therapy does not add to overall or infectious 30-day postoperative morbidity in pediatric CD patients. Two main points may help physicians to decide when the surgical option may be considered in patients with chronic refractory UC: (1) a first risk stratification can be obtained by analyzing factors at baseline and medical history, including the previous exposure to anti-TNFs; (2) during therapy with biologics, the early assessment (after 12-16 weeks of treatment) of clinical and endoscopic response is a strong predictor of the subsequent risk of colectomy.
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Necrotizing Granulomas in a Patient With Psoriasis and Sarcoidosis After Adalimumab-Medication-Induced Reaction or Reactivation of Latent Disease? (Pubmed Central) - Feb 7, 2020
Although rare reports of a "sarcoidosis-like" reaction associated with select tumor necrosis factor-alpha agents exist, to the best of our knowledge, perforating and necrotizing cutaneous granulomas after treatment with adalimumab has not been previously reported. Given the patient's history of systemic sarcoidosis, the differential diagnosis includes reactivation of latent sarcoidosis with adalimumab as a trigger.
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction. (Pubmed Central) - Feb 7, 2020
Given the patient's history of systemic sarcoidosis, the differential diagnosis includes reactivation of latent sarcoidosis with adalimumab as a trigger. No abstract available
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO. (Pubmed Central) - Feb 7, 2020
This opinion will be tested in the planned prospective CNO study. The process for establishing expert consensus opinion in CNO will be helpful for developing studies in other rare paediatric diseases.
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Tocilizumab in refractory juvenile idiopathic arthritis with associated uveitis: a case report. (Pubmed Central) - Feb 7, 2020
However, one should always pursuit JIA inactivity with IOP and inflammation control. This report supports Tocilizumab as a useful therapeutic option for JIA-associated uveitis.
- | Humira (adalimumab) / AbbVie
Trial completion date, Trial primary completion date: LADI: Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients (clinicaltrials.gov) - Feb 7, 2020
P4, N=174, Recruiting, Sponsor: Radboud University
This report supports Tocilizumab as a useful therapeutic option for JIA-associated uveitis. Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
- ||| Humira (adalimumab) / AbbVie, Tremfya (guselkumab) / J&J
New trial: TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study (clinicaltrials.gov) - Feb 6, 2020
P=N/A, N=36, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
- || Lamprene (clofazimine) / Novartis, Humira (adalimumab) / Eisai, AbbVie
Review, Journal: Medication-Induced Repigmentation of Gray Hair: A Systematic Review. (Pubmed Central) - Feb 6, 2020
There is also low-quality evidence that some vitamin B complex supplementation can promote gray hair darkening. While these compounds are not currently indicated for the treatment of gray hair, their mechanisms shed light on targets for future medications for hair repigmentation.
- | Remicade (infliximab) / J&J, NN1213 / Novo Nordisk, Humira (adalimumab) / AbbVie
Trial completion date: SUSI-CS: Stavanger IBD Study - Cross Sectional (clinicaltrials.gov) - Feb 5, 2020
P=N/A, N=210, Active, not recruiting, Sponsor: Helse Stavanger HF
While these compounds are not currently indicated for the treatment of gray hair, their mechanisms shed light on targets for future medications for hair repigmentation. Trial completion date: Nov 2020 --> Dec 2021
- ||||| Humira (adalimumab) / AbbVie
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis (clinicaltrials.gov) - Feb 5, 2020
P3, N=59, Active, not recruiting, Sponsor: AbbVie
Trial completion date: Nov 2020 --> Dec 2021 Enrolling by invitation --> Active, not recruiting | N=93 --> 59 | Trial completion date: Mar 2026 --> May 2025 | Trial primary completion date: May 2023 --> Mar 2025
- || Humira (adalimumab) / AbbVie
Trial completion date, Trial primary completion date, HEOR: Rheumatoid Arthritis Satisfaction Outcome Research (clinicaltrials.gov) - Feb 5, 2020
P=N/A, N=840, Recruiting, Sponsor: Pfizer
Enrolling by invitation --> Active, not recruiting | N=93 --> 59 | Trial completion date: Mar 2026 --> May 2025 | Trial primary completion date: May 2023 --> Mar 2025 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- | Humira (adalimumab) / AbbVie
New P4 trial, Head-to-Head: ADDORA-switch: Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (clinicaltrials.gov) - Feb 4, 2020
P4, N=84, Recruiting, Sponsor: Reade Rheumatology Research Institute
- | Orencia (abatacept) / BMS
New P4 trial: Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) (clinicaltrials.gov) - Feb 4, 2020
P4, N=60, Not yet recruiting, Sponsor: St George's, University of London
- | Humira (adalimumab) / Eisai, AbbVie
Humira is $28,999 for six weeks @abbvie (Twitter) - Feb 4, 2020
- |||| Humira (adalimumab) / Eisai, AbbVie
Clinical: 1/Has the patient had an MRE. 2/ is the TI normal. 3/ is it 1ry or 2d failure to Humira. The answers to the above ?? Would make my decision easier. Risk stratification puts her on high risk considering young age, perinatal disease. Tofa is this case would not be my 1st choice. (Twitter) - Feb 4, 2020
- || Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
Would continue tofacitinib. Would antibodies to adalimumab make a difference? Possible role for IFX in future with Aza if immunogenic failure? (Twitter) - Feb 3, 2020
- Humira (adalimumab) / Eisai, AbbVie
Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis () - Feb 3, 2020 - Abstract #AAN2020AAN_4949;
We describe 3 cases of persistent neurocysticercosis-associated inflammation that highlight both the efficacy and complications of SSAs use in neurocysticercosis. Our series emphasizes the need for further study on the use of SSAs in the treatment of neurocysticercosis-related inflammation.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Niemann-Pick disease type C presenting as very early onset inflammatory bowel disease. (Pubmed Central) - Feb 1, 2020
He did not have any typical neurological symptoms at the time of his diagnosis. He is currently doing well on biweekly adalimumab injections for his Crohn's disease and biweekly intrathecal injections of 2-hydroxypropyl-β-cyclodextrin (VTS-270) for the NPC.